MRG002

MRG002 is an investigational agent whose form is not stated in the registry developed by Shanghai Miracogen. Its molecular target is not stated in the ClinicalTrials.gov intervention record, and OnCo has not confirmed one from the sponsor's pipeline page. It is the investigational product in 2 recruiting or active industry-led phase 2 and phase 3 interventional cancer trials, including the phase 3 study NCT05754853 (A Study of MRG002 Versus Investigator's Choice of Chemotherapy in the Treatment of Patients With HER2-positive Unresectable Advanced or Metastatic Urothelial Cancer), in gastric & gastro-oesophageal junction cancer and bladder & urothelial cancer. The largest, NCT05754853, plans to enrol 290 participants with primary completion expected 2025-10. Status reflects the highest phase registered on ClinicalTrials.gov at the 2026-09-11 check; no efficacy results are recorded here.